Navigation Links
Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load; Cytoxan Preconditioning Successfully Enhances Engraftment
Date:12/6/2013

ts that had initiated TI in the SB-728-902 Cohort 5 study and an additional CCR5 delta-32 heterozygote subject from an earlier Phase 1 clinical trial of SB-728-T. One SB-728-902 Cohort 5 subject, who had the highest levels of estimated biallelically modified cells and measurable immunological responses to the virus (polyfunctional anti-gag response), demonstrated sustained control of VL at or below the limits of detection, which is ongoing for more than 20 weeks into the TI.

The SB-728-1101 study aimed to demonstrate enhanced engraftment of SB-728-T modified CD4 cells following cyclophosphamide (Cytoxan) preconditioning. Cytoxan is a drug that is used to transiently reduce the numbers of T-cells in the body, which then rapidly repopulate once the drug is discontinued and it is into this "growth" environment that SB-728-T is infused. This study was successful in showing a Cytoxan-dose dependent increase in both SB-728-T and total CD4 T-cells at the beginning of the treatment interruption, which in the top dose tested (1g/m2) approached the engraftment levels observed in CCR5 delta 32 heterozygote VL responders, and resulted in up to a two-log decrease in VL in one of three subjects who remains on TI and a 0.8-log decrease in a second subject. In the study, a total of twelve subjects were treated in three cohorts of escalating doses of Cytoxan (three subjects at 200 mg, six subjects at 500 mg/m2and three subjects at 1000 mg/m2). All doses tested were safe and well-tolerated although two of the first three subjects in the second cohort experienced Grade 2 nausea, which was reversed using an improved anti-emetic regimen that  was further tested with an additional three subjects (total of six subjects at this dose level). Cytoxan dose-dependent increases were observed in both SB-728-T and total CD4 T-cells. The study has been expanded to test an additional six subjects in two cohorts of three at Cytoxan doses of 2.0 and 3.0 g/
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
2. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
3. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
4. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
5. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
6. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
7. Sangamo BioSciences Reports First Quarter 2013 Financial Results
8. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
9. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
10. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
11. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015 HeartWare ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that its President and Chief Executive Officer, ... Canaccord Genuity 35th Annual Growth Conference at 8:30 a.m. ... being held August 12-13, 2015 at the InterContinental Boston. ...
(Date:8/4/2015)... Aug. 4, 2015  The Pittsburgh Life Sciences Greenhouse ... announced today that one of its portfolio companies, Medrobotics ... Flex ® Robotic System in the U.S.  ... proud of Medrobotics," said John W. Manzetti , ... very long way since spinning out of The Robotics ...
(Date:8/4/2015)... , Aug. 4, 2015  Intec Pharma Ltd. (the ... company focused on developing drugs based on its proprietary ... its initial public offering in the United ... at a price to the public of $6.00 per ... the ordinary shares are being offered by the Company.  ...
Breaking Medicine Technology:HeartWare Presentation At The Canaccord Genuity 35th Annual Growth Conference To Be Webcast 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 3Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3
... CHENGDU, China, Jan. 7, 2011  /PRNewswire-Asia-FirstCall/ -- Tianyin ... ), a pharmaceutical company that specializes in patented ... other pharmaceuticals today announced that the Company,s 2010 ... New York Stock Exchange Conference Room 632 on Monday, ...
... 2011 Athersys, Inc. (Nasdaq: ATHX ) today ... present at Retail Investor Confrences.com. DATE: , January 11, ... will be a live, interactive online event where investors are ... the presentation hall as well as the company,s "virtual trade ...
Cached Medicine Technology:Tianyin Pharmaceutical to Hold 2010 Shareholder Annual Meeting on March 21, 2011 at NYSE 2Athersys to Present Live at Retail Investor Conferences.com on January 11th 2
(Date:8/4/2015)... (PRWEB) , ... August 05, 2015 , ... Renowned review ... According to the latest update, MillionaireMatch.com has been ranked as the best dating service ... while looking for a life companion. It is essential that people find the right ...
(Date:8/4/2015)... ... , ... Statement by Paul Gionfriddo, President and CEO, Mental Health America , ... Act of 2015 by Senators Bill Cassidy and Christopher Murphy. It is ... , “This legislation and H.R. 2646 [The Helping Families in Mental Health ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... it has joined the American Association of Tissue Banks (AATB) as an Affiliate ... its mission “to honor donors, and to save and improve lives by promoting ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... Rhode Island ... center in the George Washington Medical Building on Wake Robin Road in Lincoln, RI. ... Wake Robin office will offer the most extensive out-patient x-ray hours in the state, ...
(Date:8/4/2015)... Los Angeles, California (PRWEB) , ... August 04, ... ... bearing drawer slides to Los Angeles commercial customers. Finding reliable hardware can ... create unfortunate liabilities. When putting an office together or designing a new ...
Breaking Medicine News(10 mins):Health News:BestMillionaireDatingSites.com Publishes Reviews of the Best Dating Sites for Wealthy Singles 2Health News:MHA Applauds Introduction of Mental Health Reform Act of 2015 2Health News:MHA Applauds Introduction of Mental Health Reform Act of 2015 3Health News:Exsurco Medical Joins AATB as Affiliate Member 2Health News:Rhode Island Medical Imaging Opens Satellite Imaging Center on Wake Robin Road in Lincoln 2Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 2Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 3Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 4
... A new examination of the origin of syphilis supports the ... aboard Christopher Columbus, ships as they sailed home from ... through sexual contact at the time, but adapted to survive ... "Syphilis has been around for 500 years," study co-leader ...
... the tsunami that devastated Japan in March could reach the ... by NOAA scientists. However, they warn there is still a ... where it,s located, where it will go, and when it ... situation on their hands: How do you deal with debris ...
... , WEDNESDAY, Dec. 28 (HealthDay News) -- Regular ... high levels of gluten and could cause problems for people ... made using barely, which contains a form of gluten called ... eliminates gluten or reduces it to very low levels, according ...
... target a single class of proteins and now scientists ... workings of those proteins critical to our health. A ... new results from a team led by Gregory Tall, Ph.D., ... Rochester Medical Center. The work was published recently in ...
... Reporter , TUESDAY, Dec. 27 (HealthDay News) -- Vegan diets ... of eating that exists on the radical fringes of vegetarianism. ... vegan diets a second look, and nutritionists now believe that ... way to live for most people. "Properly planned vegan ...
... Atherosclerosis is a disease of the major arterial blood vessels. ... and stroke. The proinflammatory molecule IL-1 has been linked to ... an antibody specific for IL-1-beta is being studied for its ... attack and stroke). However, a team of researchers led ...
Cached Medicine News:Health News:Columbus Voyage Tied to Syphilis Spread? 2Health News:Debris scatters in the Pacific Ocean, possibly heading to US 2Health News:Debris scatters in the Pacific Ocean, possibly heading to US 3Health News:Scientists fixate on Ric-8 to understand trafficking of popular drug receptor targets 2Health News:The Mainstreaming of Vegan Diets 2Health News:The Mainstreaming of Vegan Diets 3Health News:The Mainstreaming of Vegan Diets 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: